- Company
- New triple combo ‘Enerzair’ for asthma lands in 'Big 5'
- by Eo, Yun-Ho Jan 6, 2022 06:09am
- ‘Enerzair Breezhaler,’ a three-in-one triple combination therapy for asthma, can now be prescribed at general hospitals in Korea. According to industry sources, Novartis Korea’s triple combination drug ‘Enerzair Breezhaler (mometasone·indacaterol·glycopyrronium)’ that contains ICS (inhaled corticosteroids) · LABA (beta2-agonist)
- Company
- Exports of the biohealth industry surpassed 19 trillion won
- by Jan 5, 2022 05:57am
- Exports of the domestic biohealth industry hit a record high last year due to soaring demand for biosimilars, COVID-19 diagnostic kits and medical devices. Exports in related sectors reached $16.2 billion last year, exceeding $15 billion for the first time. It is expected that strong performance will continue this year due to the release of new
- Company
- Only 14% of Pharmas plan to increase jobs due to COVID-19
- by Chon, Seung-Hyun Jan 4, 2022 05:56am
- The prolonged COVID-19 pandemic is expected to bring personnel reshuffling changes to the pharmaceutical and biopharmaceutical industry. CEOs in the pharma industry said that they plan to maintain or reduce the size of new employments in their companies. In addition, 7 out of 10 CEOs predicted that while the companies will maintain the num
- Company
- 2/3 of CEOs plan to continue 'contactless' business activity
- by Kim, Jin-Gu Jan 4, 2022 05:56am
- Three years into the COVID-19 pandemic, 3 out of 4 CEOs from pharmaceutical and biopharmaceutical companies expect their company’s non-face-to-face business activities to expand further this year. The CEOs have also announced plans to maintain or reinforce their non-face-to-face business activities that settled as the ‘new normal’ in
- Company
- Strengthening sales is the top priority in competitiveness
- by Chon, Seung-Hyun Jan 3, 2022 05:57am
- Three out of five CEOs of pharmaceutical companies pointed to "strengthening sales and marketing capabilities" as the most important management strategy to expand competitiveness in the post-Corona era. The view is that it is urgent to establish an effective sales strategy due to rapid changes in the market environment. More than half of the
- Company
- Expectations rise for prescription of tumor-agnostic drugs
- by Eo, Yun-Ho Jan 3, 2022 05:56am
- Preparations to prescribe`tumor-agnostic' anticancer drugs in the field are well underway. According to industry sources, Bayer Korea’s neurotrophic tyrosine receptor kinase (NTRK) inhibitor Vitrakvi (larotrectinib) has passed the drug committee (DCs) of general hospitals in Korea including the Seoul National University Hospital. Thu
- Company
- Samsung Biologics denies rumors of Biogen's acquisition
- by Jan 3, 2022 05:55am
- Biogen shares fluctuated on reports that Samsung Group is trying to acquire U.S. pharmaceutical company Biogen for 50 trillion won. Samsung said, "It's not true."Some media recently observed that Samsung Group has begun negotiations after a preliminary review to acquire Biogen. The acquisition is expected to reach 50 trillion won. Shortly
- Company
- Record number of new homegrown drugs released this year
- by Chon, Seung-Hyun Dec 31, 2021 05:51am
- Domestic pharmaceutical and biopharmaceutical companies this year had received approval for four new drugs. This is the most amount of new drugs released in a single year since the first homegrown drug was introduced in 1999. Major companies with an annual sales record of 1 trillion won such as Yuhan Corp, Celltrion, Hanmi Pharamcetucial, and Da
- Company
- Daewoong's drug targets ₩100 bil market as 2nd P-CAB
- by Kim, Jin-Gu Dec 31, 2021 05:51am
- Daewoong Pharmaceutical succeeded in receiving approval for its potassium-competitive acid blocker (P-CAB) ‘Fexclu (fexuprazan)’ for the treatment of gastroesophageal reflux disease (GERD). It is being predicted that the new drug introduced will unfold a full-fledged competition with HK inno.N’s ‘K-CAB (tegoprazan), a GERD treatment
- Company
- Competition for KRAS targeted anticancer drugs
- by Dec 31, 2021 05:51am
- The development of treatments targeting KRAS mutations in solid cancers, including non-small cell lung cancer, is active. This year alone, seven companies were approved for nine related clinical trials. Amgen, which is leading the competition, is undergoing a domestic permit review. According to the pharmaceutical industry on the 30th, the
